Comparison · NCT01840072-e7af66b7
Active Antihypertensive Treatment vs Usual Care: A Combination of All-cause Mortality and Major Disability at the 3-month Post-treatment Follow-up.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Active Antihypertensive Treatment vs Usual Care: A Combination of All-cause Mortality and Major Disability at the 3-month Post-treatment Follow-up. Trial comparisons, record NCT01840072-e7af66b7. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01840072-e7af66b7
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.252 | 0.233 | 0.271 | wilson | |
| Risk in group 2 | 0.253 | 0.234 | 0.272 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00113 | -0.0281 | 0.0259 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.996 | 0.894 | 1.11 | log | |
| Odds ratio, group 1 over group 2 | 0.994 | 0.861 | 1.15 | log | |
| Number needed to treat, for one fewer participant with the outcome on Active Antihypertensive Treatment than on Usual Care | 883 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: usual care.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Active Antihypertensive Treatment | Active antihypertensive treatment~Active antihypertensive treatment: Initial antihypertensive treatment with angiotensin-converting enzyme inhibitors (Enalapril) and/or calcium channel blockers as second line medication; and/or diuretics as third line medications. Based on patients' baseline BP level, the first-line medication (intravenous Enalapril) can be used alone, or in combination with second-line medication (calcium channel blocker), and third-line medication (diuretics) to achieve the target systolic BP lowering by 10% to 25% within the first 24 hours after randomization and to achieve systolic BP below 140 mm Hg and diastolic BP below 90 mm Hg and maintain this BP level afterwards during the hospitalization. | 500 | 1,988 | OG001 |
| Group 2 | Usual Care | Discontinue all home BP medications. | 502 | 1,987 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- A Combination of All-cause Mortality and Major Disability at the 3-month Post-treatment Follow-up.
- Description
Major disability was defined as a score of 3 to 5 on the modified Rankin Scale at 3 months after randomization. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death
- Time frame
- 3 months
- Population
- All participants examined at 3-month posttreatment follow-up visit
Source ClinicalTrials.gov
Trial
- Title
- China Antihypertensive Trial in Acute Ischemic Stroke
- NCT number
- NCT01840072
- Phases
- NA
- Conditions
- Ischemic Stroke
- Interventions
- Active antihypertensive treatment
- Lead sponsor
- Tulane University
- Results first posted
- 2014-11-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01840072?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01840072-e7af66b7